JP2022544702A5 - - Google Patents
Info
- Publication number
- JP2022544702A5 JP2022544702A5 JP2022511203A JP2022511203A JP2022544702A5 JP 2022544702 A5 JP2022544702 A5 JP 2022544702A5 JP 2022511203 A JP2022511203 A JP 2022511203A JP 2022511203 A JP2022511203 A JP 2022511203A JP 2022544702 A5 JP2022544702 A5 JP 2022544702A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- premrna
- composition according
- exon
- canonical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026054104A JP2026108794A (ja) | 2019-08-19 | 2026-03-27 | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888887P | 2019-08-19 | 2019-08-19 | |
| US62/888,887 | 2019-08-19 | ||
| US202063049262P | 2020-07-08 | 2020-07-08 | |
| US63/049,262 | 2020-07-08 | ||
| PCT/US2020/047081 WO2021034985A1 (en) | 2019-08-19 | 2020-08-19 | Compositions and methods for modulating splicing and protein expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026054104A Division JP2026108794A (ja) | 2019-08-19 | 2026-03-27 | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544702A JP2022544702A (ja) | 2022-10-20 |
| JP2022544702A5 true JP2022544702A5 (cg-RX-API-DMAC10.html) | 2023-08-28 |
Family
ID=74659533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511203A Pending JP2022544702A (ja) | 2019-08-19 | 2020-08-19 | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
| JP2026054104A Pending JP2026108794A (ja) | 2019-08-19 | 2026-03-27 | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026054104A Pending JP2026108794A (ja) | 2019-08-19 | 2026-03-27 | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
Country Status (11)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12559747B2 (en) * | 2019-05-27 | 2026-02-24 | Vision Pharma Pty Ltd | Retinitis pigmentosa treatment |
| KR20220054401A (ko) * | 2019-09-03 | 2022-05-02 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물 |
| US20230174984A1 (en) * | 2020-05-11 | 2023-06-08 | The Florey Indtitute of Neuroscience and Mental Health | Compositions and methods for treating disorders associated with loss-of-function mutations in syngap1 |
| CN117980479A (zh) * | 2021-06-21 | 2024-05-03 | 斯托克制药公司 | 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体 |
| EP4373845A4 (en) * | 2021-07-23 | 2025-06-25 | The Children's Medical Center Corporation | Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use |
| CA3252931A1 (en) * | 2022-02-24 | 2023-08-31 | Quiver Holdings Inc. | THERAPEUTIC AGENTS FOR HAPLOINS SUFFICIENCY OF SYNGAP |
| EP4504951A4 (en) * | 2022-04-05 | 2026-07-15 | Univ Johns Hopkins | METHODS AND MATERIALS FOR TREATING NEURODEVELOPMENTAL DISORDERS ASSOCIATED WITH SYNGAP1 |
| WO2023212625A1 (en) * | 2022-04-28 | 2023-11-02 | AcuraStem Incorporated | Syf2 antisense oligonucleotides |
| US20250313832A1 (en) * | 2022-05-13 | 2025-10-09 | The Trustees Of The University Of Pennsylvania | Compositions for treating syngap-1 related neurodevelopmental disorders |
| JP2025522625A (ja) * | 2022-06-28 | 2025-07-15 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | オリゴヌクレオチド |
| WO2025090628A1 (en) * | 2023-10-23 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies |
| WO2025111249A2 (en) * | 2023-11-20 | 2025-05-30 | Dana-Farber Cancer Institute, Inc. | Methods, kits and systems for determining sarcomatoid differentiation of renal cell carcinoma and methods for treating based on the same |
| GB202401412D0 (en) * | 2024-02-02 | 2024-03-20 | Harness Therapeutics Ltd | Functional nucleic acid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009064920A2 (en) * | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
| JP2012507989A (ja) * | 2008-11-07 | 2012-04-05 | センター ホスピタライヤー ユニヴェルシテール サント−ジュスティーヌ | Syngap1機能不全ならびに精神遅滞の診断および治療用途でのその使用 |
| CN107109411B (zh) * | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| CN108603230A (zh) * | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| CN116059236A (zh) * | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| CA3005131A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of tuberous sclerosis complex |
| JP7049247B2 (ja) * | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 腎臓病の処置のための組成物と方法 |
| WO2017106283A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of liver diseases |
| CA3005247A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of polycystic kidney disease |
| JP7036723B2 (ja) * | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| JP2019535789A (ja) * | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス,インコーポレーテッド | Rnaスプライシングを調節する方法 |
| KR20260009385A (ko) * | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| LT3700570T (lt) * | 2017-10-23 | 2025-04-10 | Stoke Therapeutics, Inc. | Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui |
-
2020
- 2020-08-19 KR KR1020227008965A patent/KR20220104677A/ko active Pending
- 2020-08-19 MX MX2022002198A patent/MX2022002198A/es unknown
- 2020-08-19 CA CA3147970A patent/CA3147970A1/en active Pending
- 2020-08-19 EP EP20855637.3A patent/EP4017979A4/en active Pending
- 2020-08-19 WO PCT/US2020/047081 patent/WO2021034985A1/en not_active Ceased
- 2020-08-19 AU AU2020334067A patent/AU2020334067A1/en active Pending
- 2020-08-19 BR BR112022002905A patent/BR112022002905A2/pt unknown
- 2020-08-19 CN CN202080073358.0A patent/CN114746550A/zh active Pending
- 2020-08-19 JP JP2022511203A patent/JP2022544702A/ja active Pending
-
2022
- 2022-02-13 IL IL290595A patent/IL290595A/en unknown
- 2022-02-16 US US17/673,226 patent/US20220290142A1/en active Pending
-
2026
- 2026-03-27 JP JP2026054104A patent/JP2026108794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2692886T3 (es) | Métodos y medios para el salto eficaz de al menos uno de los siguientes exones del gen de distrofia muscular de Duchenne humana: 43, 46, 50-53 | |
| ES2551154T3 (es) | Procedimiento para la eficiente omisión del exón (44) en distrofia muscular de Duchenne y medios asociados | |
| JP6791877B2 (ja) | デュシェンヌ型筋ジストロフィーを治療するためのダイナミン2阻害剤 | |
| TWI899403B (zh) | Rna治療劑及其使用方法 | |
| US20230235298A1 (en) | Phenylalanine hydroxylase variants and uses thereof | |
| WO2024263915A2 (en) | Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof | |
| JP7863050B2 (ja) | siRNAを使用してPRDM2/RIZタンパク質の発現を調節するがん治療 | |
| EP3177313B1 (en) | Telomerase reverse transcriptase-based therapies for treatment of conditions associated with myocardial infarction | |
| JP7664233B2 (ja) | 治療 | |
| JP2018519250A (ja) | 治療薬としてのsmad7遺伝子送達 | |
| CN116490216A (zh) | Sarna和mrna调节剂联合治疗sma | |
| CN120775846A (zh) | 反义寡核苷酸及其在疼痛治疗中的应用 | |
| WO2025147949A1 (zh) | 基因编辑系统及其应用 | |
| CA3125310A1 (en) | Double stranded rna and uses thereof | |
| JP2024507717A5 (cg-RX-API-DMAC10.html) | ||
| CN119233981A (zh) | 用于组织特异性表达的启动子开关 | |
| US20230078498A1 (en) | Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis | |
| EP4366785A1 (en) | Treatment for tyrosine degradation-associated disorders | |
| US20250345462A1 (en) | Compositions and methods for treating liver disease | |
| WO2025253282A1 (en) | Small interfering nucletides (sioligo) for the treatment of cole-carpenter syndrome (ccs) | |
| WO2026009728A1 (ja) | アンチセンス核酸及びその使用 | |
| KR101888104B1 (ko) | MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| JP2025084707A (ja) | アンチセンス核酸およびその利用 | |
| WO2021085592A1 (ja) | 疾患特異的なcol3a1変異アレルの遺伝子発現を抑制する核酸および血管型エーラス・ダンロス症候群を処置するための医薬組成物 | |
| WO2025072604A1 (en) | Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1) |